Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SPI1
REST API REST API
Homo sapiens
SPI1 is differentially expressed in 197 experiments: 63 organism parts: lung, bone marrow, ... (61 more);, 205 disease states: normal, glioblastoma, ... (203 more);, 73 cell types 185 cell lines 23 compound treatments and 59 other conditions.
Synonyms SFPI1, SPI-A, SPI-1, PU.1, OF
Orthologs E1BJR2_BOVIN (Bos taurus)   Sfpi1 (Mus musculus)   spi1 (Danio rerio)   spi1l (Danio rerio)   E1BZN0_CHICK (Gallus gallus)   Spi1 (Rattus norvegicus)   spi1 (Xenopus laevis)   SPI1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, nuclear chromatin, transcription, DNA-dependent, sequence-specific DNA binding, induction of apoptosis, nucleus, somatic stem cell maintenance, negative regulation of transcription from RNA polymerase II promoter, regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, RNA binding, myeloid leukocyte differentiation, negative regulation of MHC class II biosynthetic process, regulation of erythrocyte differentiation, granulocyte differentiation, erythrocyte differentiation, lymphocyte differentiation, lymphoid progenitor cell differentiation, vasculature development, anatomical structure regression, myeloid dendritic cell differentiation, macrophage differentiation, sequence-specific DNA binding transcription factor activity, RNA polymerase II transcription factor binding
InterPro Term Ets
UniProt Accession P17947, F5GZ94, F5H3K6
Search EB-eye ENSG00000066336
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-GEOD-1563, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-1880, E-MEXP-1006, E-GEOD-2450, E-GEOD-24147, ... (19 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081
HL-60
1
2
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
Ag10750
1
E-MTAB-62
MJ
1
E-MTAB-37
NCIH508
1
E-MTAB-37
HepG2
1
E-MTAB-37
179 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-3920, E-MEXP-66, E-GEOD-20677, E-GEOD-13987, ... (38 experiments)

Factor Value U/D Experiments
endothelial cell
2
E-GEOD-19240, E-GEOD-3920
whole blood
2
E-MTAB-25, E-GEOD-3026
unstimulated polymorphonuclear leukocyte
1
E-GEOD-935
purified CLL B cells from peripheral blood
1
E-GEOD-22529
epithelial cell
1
E-GEOD-10797
naive T cell
1
E-GEOD-1460
67 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-22529, E-GEOD-15960, E-GEOD-1869, ... (48 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-4290, E-MTAB-62, E-GEOD-4412, E-MEXP-567
control
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-MTAB-37
prostate carcinoma
2
E-MTAB-62, E-GEOD-96
Burkitt's lymphoma
1
2
E-MTAB-37, E-GEOD-96, E-GEOD-1880
199 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (15 experiments)

Factor Value U/D Experiments
none
1
5
E-MEXP-1601, E-GEOD-412, E-GEOD-5824, E-TABM-782, E-TABM-868, ... (6 experiments)
vanadium pentoxide
1
E-GEOD-5339
rapamycin
1
E-GEOD-5824
HMB-PP (phosphoantigen)
1
E-MEXP-1601
no estradiol
1
E-GEOD-20081
lipopolysaccharide
1
E-TABM-868
17 more value(s).


Biopsy tissue

studied in E-GEOD-5851

Factor Value U/D Experiments
abdomen (soft tissue mass)
1
E-GEOD-5851


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-2171, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21589, E-GEOD-16363, E-GEOD-2149, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MTAB-62

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-17385

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-TABM-321

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1446, E-GEOD-9764, E-MEXP-2146

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (28 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22229, E-GEOD-19703, E-GEOD-1309, E-GEOD-22309

Population
studied in E-MTAB-197, E-GEOD-4342

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-1643, E-GEOD-2466

Stimulation
studied in E-GEOD-4883, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-12198 ... (5 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Tumor size
studied in E-GEOD-3494

Processing time: 0.318 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM